Clear Cell Adenocarcinoma

Categories: Cancer diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Clear Cell Adenocarcinoma

MalaCards integrated aliases for Clear Cell Adenocarcinoma:

Name: Clear Cell Adenocarcinoma 11 14 16
Mesonephroma 11 43 71
Water-Clear Cell Adenocarcinoma 11 71
Adenocarcinoma, Clear Cell 43 71
Mesonephroid Clear Cell Carcinoma 11
Water-Clear Cell Carcinoma 11
Adenocarcinoma Clear Cell 53
Clear-Cell Adenocarcinoma 75
Mesonephroma, Malignant 11
Malignant Mesonephroma 11
Wolffian Duct Neoplasm 11
Mesonephric Tumor 71


External Ids:

Disease Ontology 11 DOID:4468
UMLS 71 C0025490 C0206681 C0334322 more

Summaries for Clear Cell Adenocarcinoma

Disease Ontology: 11 An adenocarcinoma that derives from epithelial cells which have clear cytoplasm.

MalaCards based summary: Clear Cell Adenocarcinoma, also known as mesonephroma, is related to urethra clear cell adenocarcinoma and ovarian clear cell adenocarcinoma. An important gene associated with Clear Cell Adenocarcinoma is MUC16 (Mucin 16, Cell Surface Associated), and among its related pathways/superpathways are Toll-like receptor signaling pathway and Endometrial cancer. The drugs Lenograstim and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include ovary, cervix and lymph node, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Decreased viability in pancreas lineage

Wikipedia: 75 Clear-cell adenocarcinoma is a type of adenocarcinoma that shows clear... more...

Related Diseases for Clear Cell Adenocarcinoma

Diseases related to Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 407)
# Related Disease Score Top Affiliating Genes
1 urethra clear cell adenocarcinoma 33.0 PAX8 KRT7
2 ovarian clear cell adenocarcinoma 32.4 TP53 HNF1B ARID1A
3 endometrial clear cell adenocarcinoma 32.4 NAPSA HNF1B
4 cervical clear cell adenocarcinoma 32.3 NAPSA KRT7
5 wolffian duct adenoma 32.1 PAX8 MME KRT7 KLK3
6 bladder clear cell adenocarcinoma 31.6 TP53 PAX8 NAPSA MME KRT7
7 urethra adenocarcinoma 31.3 PAX8 KRT7
8 cervical adenocarcinoma 30.9 TP53 MUC16 KRT7 IFI27
9 appendix adenocarcinoma 30.9 TP53 SMAD4 KRT7
10 endometrial adenocarcinoma 30.7 TP53 PAX8 KRT7
11 endodermal sinus tumor 30.6 MUC16 KRT7 KLK3 ACP3
12 adenoma 30.5 TP53 SMAD4 SMAD3 KRT7 CCND1
13 adenocarcinoma 30.5 TP53 SMAD4 SMAD3 SMAD2 NAPSA KRT7
14 ovary adenocarcinoma 30.5 TP53 PAX8 MUC16 KRT7 INHBA ARID1A
15 urethral diverticulum 30.5 PAX8 NAPSA KRT7 KLK3
16 clear cell adenofibroma 30.4 NAPSA ARID1A
17 collecting duct carcinoma 30.4 PAX8 MME KRT7
18 vaginal cancer 30.4 TP53 MME KRT7
19 suppression of tumorigenicity 12 30.2 TP53 SMAD4 KLK3
20 bladder adenocarcinoma 30.2 TP53 NAPSA KRT7 KLK3
21 colon adenocarcinoma 30.2 TP53 SMAD4 SMAD3 SMAD2 CCND1 ARID1A
22 transitional cell carcinoma 30.1 TP53 MUC16 KRT7 KLK3
23 polycystic liver disease 1 with or without kidney cysts 30.1 MUC16 KRT7 HNF1B
24 male urethral cancer 30.0 TP53 KRT7 KLK3
25 urinary tract obstruction 30.0 SMAD3 SMAD2 KRT7 KLK3
26 nephrogenic adenoma 30.0 PAX8 NAPSA MME KRT7 KLK3
27 pancreatic adenocarcinoma 30.0 TP53 SMAD4 SMAD2 CCND1
28 colorectal adenoma 30.0 TP53 SMAD4 CCND1
29 hydronephrosis 30.0 MME KRT7 KLK3
30 small-cell carcinoma of the ovary of hypercalcemic type 30.0 TP53 ARID1A
31 mucinous adenocarcinoma 30.0 TP53 SMAD4 PAX8 NAPSA KRT7
32 vulva cancer 29.9 TP53 KRT7 CCND1
33 endosalpingiosis 29.9 TP53 PAX8 KRT7
34 fallopian tube carcinoma 29.9 TP53 PAX8 KRT7
35 renal cell carcinoma, papillary, 1 29.9 TP53 PAX8 MME KRT7
36 squamous cell carcinoma 29.9 TP53 SMAD4 PTHLH KRT7 CCND1
37 ovarian cancer 29.9 TP53 SMAD4 SMAD3 SMAD2 MUC16 KRT7
38 cystadenocarcinoma 29.8 TP53 PAX8 MUC16 KRT7 ARID1A
39 ovarian serous cystadenocarcinoma 29.8 TP53 SMAD4 PAX8 MUC16
40 papilloma 29.8 TP53 KRT7 IFI27 CCND1
41 adenocarcinoma in situ 29.8 TP53 NAPSA KRT7
42 adrenal cortical carcinoma 29.7 TP53 SMAD4 PAX8 CCND1
43 nephrogenic adenoma of the urethra 29.7 PAX8 MME KRT7 KLK3
44 ovarian clear cell carcinoma 29.7 TP53 NAPSA HNF1B ARID1A
45 endometrial cancer 29.7 TP53 SMAD4 SMAD3 SMAD2 MUC16 MME
46 cervix carcinoma 29.7 TP53 PAX8 KRT7 CCND1
47 squamous cell carcinoma, head and neck 29.6 TP53 SMAD4 SMAD3 SMAD2 CCND1
48 urethral benign neoplasm 29.6 TP53 PAX8 MME KRT7 KLK3
49 serous cystadenocarcinoma 29.6 TP53 PAX8 NAPSA MUC16 KRT7 HNF1B
50 rhabdomyosarcoma 29.5 TP53 SMAD4 SMAD3 SMAD2 MME KRT7

Graphical network of the top 20 diseases related to Clear Cell Adenocarcinoma:

Diseases related to Clear Cell Adenocarcinoma

Symptoms & Phenotypes for Clear Cell Adenocarcinoma

GenomeRNAi Phenotypes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

25 (show all 19)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.62 SMAD2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.62 SMAD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.62 SMAD2 SMAD4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-134 9.62 CCND1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.62 CCND1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.62 PAX8
7 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.62 SMAD2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-174 9.62 SMAD2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-195 9.62 SMAD4
10 Increased shRNA abundance (Z-score > 2) GR00366-A-203 9.62 SMAD2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-205 9.62 SMAD2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.62 CCND1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.62 CCND1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.62 CCND1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-212 9.62 SMAD4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.62 SMAD2 SMAD4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.62 CCND1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.62 SMAD4
19 Decreased viability in pancreas lineage GR00235-A 9.35 ARID1A CCND1 KRT7 SMAD3 TP53

MGI Mouse Phenotypes related to Clear Cell Adenocarcinoma:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.25 ARID1A CCND1 HNF1B IFI27 INHBA KRT7
2 endocrine/exocrine gland MP:0005379 10.15 ACP3 ARID1A CCND1 HNF1B INHBA PAX8
3 normal MP:0002873 10.13 ARID1A CCND1 INHBA KLK3 PAX8 PTHLH
4 neoplasm MP:0002006 10.1 ACP3 ARID1A CCND1 PTHLH SMAD2 SMAD3
5 renal/urinary system MP:0005367 10.06 HNF1B INHBA KRT7 PAX8 PTHLH SMAD3
6 liver/biliary system MP:0005370 10.03 HNF1B MME PTHLH SLC2A4 SMAD2 SMAD3
7 digestive/alimentary MP:0005381 9.97 CCND1 HNF1B INHBA PTHLH SLC2A4 SMAD2
8 cellular MP:0005384 9.97 ARID1A CCND1 HNF1B INHBA KRT7 MME
9 craniofacial MP:0005382 9.91 ARID1A CCND1 INHBA PAX8 PTHLH SMAD2
10 cardiovascular system MP:0005385 9.7 ARID1A CCND1 IFI27 KLK3 PAX8 PTHLH
11 reproductive system MP:0005389 9.36 ACP3 ARID1A CCND1 INHBA MUC16 PAX8

Drugs & Therapeutics for Clear Cell Adenocarcinoma

Drugs for Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Lenograstim Approved, Investigational Phase 3 135968-09-1
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
Rucaparib Approved, Investigational Phase 3 283173-50-2 9931954
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60699 60700
Olaparib Approved Phase 3 763113-22-0 23725625
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
Metformin Approved Phase 2, Phase 3 1115-70-4, 657-24-9 4091
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
Niraparib Approved, Investigational Phase 3 1038915-60-4 24958200
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
Cediranib Investigational Phase 3 288383-20-0 9933475
Maleic acid Experimental, Investigational Phase 3 110-16-7, 110-17-8 444266 444972
Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
19 Carotenoids Phase 3
20 Adjuvants, Immunologic Phase 3
21 Immunologic Factors Phase 3
22 Angiogenesis Inhibitors Phase 3
23 Anti-Bacterial Agents Phase 2, Phase 3
24 topoisomerase I inhibitors Phase 2, Phase 3
25 Antimitotic Agents Phase 3
26 Poly(ADP-ribose) Polymerase Inhibitors Phase 3
27 Tubulin Modulators Phase 3
28 Antibiotics, Antitubercular Phase 2, Phase 3
29 Liposomal doxorubicin Phase 2, Phase 3
30 Protein Kinase Inhibitors Phase 3
31 Antiviral Agents Phase 3
32 Anti-Infective Agents Phase 3
33 Antimetabolites Phase 3
34 Immunosuppressive Agents Phase 3
35 Taxane Phase 3 108169
36 Hypoglycemic Agents Phase 2, Phase 3
37 Albumin-Bound Paclitaxel Phase 3
38 Tin Fluorides Phase 3
Vinblastine Approved Phase 2 865-21-4 241903 13342
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
Nintedanib Approved Phase 2 656247-17-5 135423438 9809715
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
Iodine Approved, Investigational Phase 2 7553-56-2 807
Ipilimumab Approved Phase 2 477202-00-9
Levoleucovorin Approved, Experimental, Investigational Phase 1, Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
Anastrozole Approved, Investigational Phase 2 120511-73-1 2187
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820

Interventional clinical trials:

(show top 50) (show all 107)
# Name Status NCT ID Phase Drugs
1 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
2 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Unknown status NCT00807768 Phase 3 Carboplatin;Paclitaxel
3 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Completed NCT00951496 Phase 3 Carboplatin;Cisplatin;Paclitaxel
4 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
5 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
6 Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy Recruiting NCT04575935 Phase 3 Chemotherapy
7 Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients Recruiting NCT04227522 Phase 3 Rucaparib;Placebos
8 A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Platinum-doublet Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076) Recruiting NCT05281471 Phase 3 Platinum chemotherapy: carboplatin (preferred) or cisplatin;Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin;Bevacizumab (or biosimilar)
9 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
10 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer Active, not recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
11 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Active, not recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
12 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
13 A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
14 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Active, not recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
15 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
16 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
17 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Active, not recruiting NCT03422198 Phase 3
18 Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel Active, not recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
19 A Phase III Randomized, Open Label Study of A Phase III Randomized, Open Label Study of NiraParib Maintenance After Carboplatin and Paclitaxel in optimaLly debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (N-Plus) Not yet recruiting NCT05460000 Phase 3 3 cycles chemotherapy instead of 6 cycles chemotherapy;6 cycles chemotherapy
20 Interleukin-2, Interferon Alpha,Capecitabine and Vinblastin for Treatment of Metastatic Renal Cell Carcinoma: A Multicenter Study Unknown status NCT00226798 Phase 2 Capecitabine (Xeloda)
21 A Multicentre Phase II Randomised Trial of Durvalumab (MEDI4736) Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas (MOCCA) Unknown status NCT03405454 Phase 2 durvalumab;standard chemotherapy
22 A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Unknown status NCT02866370 Phase 2 Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
23 A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma Completed NCT01097746 Phase 2 Carboplatin;Paclitaxel
24 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
25 A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum Completed NCT02315430 Phase 2 Cabozantinib S-malate
26 A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT02853318 Phase 2 Cyclophosphamide
27 A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT02923739 Phase 2 Paclitaxel
28 A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
29 A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
30 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
31 A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01011933 Phase 2 Selumetinib
32 A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01132820 Phase 2 Cediranib Maleate
33 A Phase II Evaluation of SU11248 (Sunitinib Malate) (NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma Completed NCT00979992 Phase 2 Sunitinib Malate
34 A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01642082 Phase 2
35 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
36 A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium Completed NCT01210222 Phase 2
37 A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
38 Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas Completed NCT01914510 Phase 2 ENMD-2076
39 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
40 A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
41 A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma Completed NCT00025467 Phase 2 thalidomide
42 Evaluation of the Efficacy of Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Completed NCT01824615 Phase 2 Sunitinib
43 A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab Recruiting NCT04739800 Phase 2 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
44 MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2 Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
45 EON: A Single-Arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer Recruiting NCT05026606 Phase 2
46 Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
47 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Recruiting NCT03866382 Phase 2 Cabozantinib S-malate
48 A Phase II Clinical Trial Evaluating the Combination of Onapristone With Anastrozole for Women With Refractory Hormone Receptor Positive Endometrial Cancer Recruiting NCT04719273 Phase 2 Extended-release Onapristone;Anastrozole
49 BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Recruiting NCT03355976 Phase 2 Nivolumab;Ipilimumab
50 A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma Recruiting NCT05112601 Phase 2

Search NIH Clinical Center for Clear Cell Adenocarcinoma

Cochrane evidence based reviews: mesonephroma

Genetic Tests for Clear Cell Adenocarcinoma

Anatomical Context for Clear Cell Adenocarcinoma

Organs/tissues related to Clear Cell Adenocarcinoma:

MalaCards : Ovary, Cervix, Lymph Node, Uterus, Prostate, Kidney, T Cells

Publications for Clear Cell Adenocarcinoma

Articles related to Clear Cell Adenocarcinoma:

(show top 50) (show all 1060)
# Title Authors PMID Year
Expression of glucose transporters in epithelial ovarian carcinoma: correlation with clinical characteristics and tumor angiogenesis. 53 62
17611657 2007
MMAC tumor supressor gene expression in ovarian endometriosis and ovarian adenocarcinoma. 53 62
17713092 2007
The autocrine effect of activin A on human ovarian clear cell adenocarcinoma cells. 53 62
16820918 2006
PTEN expression in clear cell adenocarcinoma of the ovary. 53 62
16290000 2006
Clear cell adenocarcinoma of the female urethra showing strong immunostaining for prostate-specific antigen. 53 62
11251541 2001
Hypercalcemia due to parathyroid hormone-related protein produced by primary ovarian clear cell adenocarcinoma: case report. 53 62
10637074 2000
Clear cell adenocarcinoma and nephrogenic adenoma of the urethra and urinary bladder: a histopathologic and immunohistochemical comparison. 53 62
9865832 1998
Ovarian vein vs peripheral blood CA125 serum levels: a comparative study. 53 62
9234924 1997
[A case of clear cell adenocarcinoma of the female urethra]. 53 62
7645457 1995
Clear cell adenocarcinoma of the female urethra showing positive staining with antibodies to prostate-specific antigen and prostatic acid phosphatase. 53 62
7536368 1995
Nephrogenic adenoma of the prostatic urethra involving the prostate gland: a clinicopathologic and immunohistochemical study of eight cases. 53 62
7512941 1994
Synchronous primary malignancies in ovarian cancer and liver angiosarcoma. 62
36217325 2022
GATA3 expression in clear cell adenocarcinoma of the lower urinary tract: a potential diagnostic pitfall. 62
36320040 2022
Female urethral carcinoma: a contemporary review of the clinicopathologic features, with emphasis on the histoanatomic landmarks and potential staging issues. 62
36037997 2022
Postmenopausal Vaginal and Cervical Cancer Risk Related to In Utero Diethylstilbestrol Exposure. 62
36222810 2022
Primary clear cell adenocarcinoma of the vagina not associated with diethylstilbestrol: A case report. 62
35987029 2022
Radical trachelectomy and adjuvant vaginal brachytherapy to preserve fertility in pediatric cervical adenocarcinoma. 62
35973904 2022
Nephrogenic Adenoma Intermixed With Urothelial Carcinoma. 62
35976666 2022
Risk of clear-cell adenocarcinoma of the vagina and cervix among US women with potential exposure to diethylstilbestrol in utero. 62
35767133 2022
Implementation of Image-Guided Brachytherapy for Pediatric Vaginal Cancers: Feasibility and Early Clinical Results. 62
35805018 2022
Diagnosis of Lung Adenocarcinoma with Clear Cell Features in Pleural Effusion: Cytomorphologic Features, Immunocytochemical Studies, and Differential Diagnosis. 62
36277803 2022
Laparoscopic posterior pelvic exenteration for clear cell adenocarcinoma arising in an episiotomy scar. 62
35086165 2022
Primary clear cell adenocarcinoma of female urinary tract: a case report and literature review. 62
35751118 2022
Clear cell adenocarcinoma arising from anterior abdominal wall cesarean section scar endometriosis treated with excision and the addition of Trastuzumab for adjuvant chemotherapy: A case report. 62
35574241 2022
Renal metastasis of ovarian granulosa cell tumor. 62
35509773 2022
[Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors]. 62
35658326 2022
Vesical clear cell adenocarcinoma of Müllerian origin treated conservatively with partial cystectomy. 62
35383096 2022
[Spontaneous rupture of kidney tumor. Successful surgical treatment]. 62
35274864 2022
Cervical cytology in the detection of uterine clear cell carcinoma: Diagnostic predictors from a case-control study. 62
34619807 2022
Clear Cell Adenocarcinoma In Situ as a Potential Precursor Lesion for Sporadic Invasive Endocervical Clear Cell Adenocarcinoma. 62
35283444 2022
Pathological examination of a placenta leading to the diagnosis of endometrial carcinoma: A case report. 62
34909202 2022
Recent Trends in the Incidence of Clear Cell Adenocarcinoma and Survival Outcomes: A SEER Analysis. 62
35282450 2022
Factors Associated with Patient Survival in Clear Cell Adenocarcinoma of the Cervix: A Single-Center Experience in China. 62
35535144 2022
Successful treatment of a 19-year-old patient with locally advanced clear cell adenocarcinoma of the uterine cervix using recombinant human adenovirus type 5 (Oncorine) combined with chemoradiotherapy: a case report. 62
35071441 2021
Distinct mutational status in GATA3-Positive clear cell adenocarcinoma of the urinary tract: A CASE report. 62
34401347 2021
Primary clear cell adenocarcinoma of prostate: A diagnostic challenge. 62
34759659 2021
Female Urethral Clear Cell Adenocarcinoma: A Case Report. 62
34175333 2021
[Clear cell adenocarcinoma in the prostate:report of a case]. 62
34496508 2021
Screening for cancers of the cervix and vagina for women exposed to diethylstilbestrol (DES) in utero. 62
33310134 2021
Immunochemical analysis of iron transporters and M2 macrophages in ovarian endometrioma and clear cell adenocarcinoma. 62
34194738 2021
A Rare Case of Clear Cell Cervical Carcinoma to a Woman, 50 Years After Diethylstilbestrol Exposure for Lactation Suppression. 62
34589362 2021
Uncommon Cervical Lesions: A Review and Discussion of the Differential Diagnosis. 62
33091926 2021
Primary Clear Cell Carcinoma of the Pancreas: A Systematic Review. 62
34150416 2021
Clear cell carcinoma of the urinary bladder: a systematic review. 62
33462714 2021
Intensity-modulated radiotherapy combined with intracavitary brachytherapy for locally advanced cervical cancer with uterus didelphys. 62
33718560 2021
Plasma cell neoplasms of the bladder: a series of 9 cases. 62
33639141 2021
Metastases from renal cell carcinoma-Report of three unpredictable cases and literature review. 62
34100413 2021
Early stage clear cell adenocarcinoma coexisting with tubular adenoma and adenoma with clear cell change in the colon. 62
33420668 2021
Clear-Cell Adenocarcinoma of the Gallbladder with Alpha-Fetoprotein Production: A Case Report and Review of the Literature. 62
33981682 2021
Mesonephric (Wolffian-derived) Adenocarcinoma of the Female Urethra. 62
33284194 2021

Variations for Clear Cell Adenocarcinoma

Copy number variations for Clear Cell Adenocarcinoma from CNVD:

# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 218693 7 116312458 116438439 Amplification MET Clear cell adenocarcinoma
2 266962 Y 174481503 174538309 Duplication AZF1 Clear cell adenocarcinoma

Expression for Clear Cell Adenocarcinoma

Search GEO for disease gene expression data for Clear Cell Adenocarcinoma.

Pathways for Clear Cell Adenocarcinoma

Pathways related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
6 12.11 TP53 SMAD4 SMAD3 SMAD2
Show member pathways
8 12.08 TP53 SMAD4 SMAD2 CCND1
9 11.94 TP53 SMAD4 SMAD3 SMAD2 CCND1
Show member pathways
11 11.86 TP53 SMAD4 SMAD3 INHBA
Show member pathways
13 11.84 SMAD4 SMAD3 SMAD2
Show member pathways
15 11.82 TP53 SMAD4 SMAD3 CCND1
Show member pathways
Show member pathways
18 11.74 TP53 SMAD4 SMAD3
20 11.71 TP53 SMAD3 INHBA
21 11.7 SMAD4 SMAD3 SMAD2
22 11.69 CCND1 SMAD4 TP53
23 11.67 SMAD4 SMAD3 SMAD2
24 11.65 TP53 SMAD4 SMAD3 SMAD2
25 11.6 SMAD4 SMAD2 CCND1
Show member pathways
27 11.52 SMAD4 SMAD3 SMAD2
28 11.49 SMAD4 SMAD3 SMAD2
29 11.35 SMAD2 SMAD3 TP53
30 11.32 SMAD4 SMAD3 SMAD2
31 11.3 TP53 SMAD4 SMAD3 CCND1
Show member pathways
33 11.17 SMAD4 SMAD3 SMAD2
34 11.1 SMAD4 SMAD3 SMAD2
Show member pathways
37 10.86 SMAD4 SMAD3 SMAD2
38 10.73 SMAD4 SMAD3 SMAD2
39 10.66 SMAD4 SMAD3 SMAD2
Show member pathways

GO Terms for Clear Cell Adenocarcinoma

Cellular components related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulator complex GO:0005667 9.96 TP53 SMAD4 SMAD3 SMAD2 HNF1B
2 activin responsive factor complex GO:0032444 9.46 SMAD4 SMAD2
3 heteromeric SMAD protein complex GO:0071144 9.43 SMAD4 SMAD3 SMAD2
4 SMAD protein complex GO:0071141 9.1 SMAD4 SMAD3 SMAD2

Biological processes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell population proliferation GO:0008285 10.34 TP53 SMAD4 SMAD3 SMAD2 PTHLH INHBA
2 positive regulation of DNA-templated transcription GO:0045893 10.31 TP53 SMAD4 SMAD3 SMAD2 PAX8 INHBA
3 anatomical structure morphogenesis GO:0009653 10.21 PAX8 SMAD2 SMAD3 SMAD4
4 negative regulation of cell growth GO:0030308 10.18 INHBA SMAD3 SMAD4 TP53
5 kidney development GO:0001822 10.13 SMAD4 PAX8 MME HNF1B
6 transforming growth factor beta receptor signaling pathway GO:0007179 10.13 TP53 SMAD4 SMAD3 SMAD2
7 extrinsic apoptotic signaling pathway GO:0097191 10.1 SMAD3 INHBA IFI27
8 positive regulation of miRNA transcription GO:1902895 10.09 TP53 SMAD4 SMAD3
9 positive regulation of epithelial to mesenchymal transition GO:0010718 10.09 SMAD4 SMAD3 SMAD2
10 SMAD protein signal transduction GO:0060395 9.97 INHBA SMAD2 SMAD3 SMAD4
11 mesoderm formation GO:0001707 9.95 SMAD3 SMAD2 INHBA
12 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.95 SMAD4 SMAD3 SMAD2
13 adrenal gland development GO:0030325 9.93 SMAD4 SMAD3 SMAD2
14 pronephros development GO:0048793 9.9 PAX8 HNF1B
15 positive regulation of follicle-stimulating hormone secretion GO:0046881 9.89 SMAD4 INHBA
16 developmental growth GO:0048589 9.89 SMAD4 SMAD3 SMAD2
17 regulation of transforming growth factor beta2 production GO:0032909 9.84 SMAD4 SMAD3
18 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.81 HNF1B PAX8
19 gastrulation GO:0007369 9.8 TP53 SMAD4 SMAD3 SMAD2
20 paraxial mesoderm morphogenesis GO:0048340 9.73 SMAD2 SMAD3
21 SMAD protein complex assembly GO:0007183 9.73 SMAD4 SMAD3 SMAD2
22 mesonephric tubule development GO:0072164 9.57 PAX8 HNF1B
23 endoderm development GO:0007492 9.55 SMAD4 SMAD3 SMAD2 HNF1B
24 regulation of binding GO:0051098 9.43 SMAD4 SMAD3 SMAD2
25 activin receptor signaling pathway GO:0032924 9.23 SMAD4 SMAD3 SMAD2 INHBA

Molecular functions related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription cis-regulatory region binding GO:0000976 9.97 TP53 SMAD4 SMAD3 PAX8 HNF1B
2 RNA polymerase II-specific DNA-binding transcription factor binding GO:0061629 9.85 IFI27 SMAD2 SMAD3 SMAD4 TP53
3 R-SMAD binding GO:0070412 9.73 SMAD4 SMAD3 SMAD2
4 SMAD binding GO:0046332 9.67 SMAD4 SMAD3 SMAD2
5 cis-regulatory region sequence-specific DNA binding GO:0000987 9.5 TP53 SMAD3 SMAD2 HNF1B
6 I-SMAD binding GO:0070411 9.1 SMAD4 SMAD3 SMAD2

Sources for Clear Cell Adenocarcinoma

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....